On August 13, 2026, the clinical trial registry listed an update for the study titled "A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer." This is a Phase 1 trial registered under identifier NCT03332797. The trial involves triptorelin as an LHRH agonist option used in combination with GDC-9545, with or without palbociclib, in patients with locally advanced or metastatic estrogen receptor-positive breast cancer.
The current trial status is listed as active, not recruiting. This means the study is ongoing but is no longer enrolling new participants at this time. No results have been posted in connection with this status update. The event data does not include information on efficacy, safety outcomes, or trial conclusions.
This update reflects only the trial's recruitment and operational status as of the date listed. Readers interested in the background of triptorelin, including its regulatory status and general use as an LHRH agonist, can consult the compound overview for additional context.